The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is to obtain an early and deep tumour burden reduction, up to the level of complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study a...

Full description

Bibliographic Details
Main Authors: Terragna, Carolina, Remondini, Daniel, Martello, Marina, Zamagni, Elena, Pantani, Lucia, Patriarca, Francesca, Pezzi, Annalisa, Levi, Giuseppe, Offidani, Massimo, Proserpio, Ilaria, De Sabbata, Giovanni, Tacchetti, Paola, Cangialosi, Clotilde, Ciambelli, Fabrizio, Viganò, Clara Virginia, Dico, Flores Angela, Santacroce, Barbara, Borsi, Enrica, Brioli, Annamaria, Marzocchi, Giulia, Castellani, Gastone, Martinelli, Giovanni, Palumbo, Antonio, Cavo, Michele
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891075/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891075/

Similar Items